Jennifer Amsler1, Iveta Kysela1, Christoph Tappeiner2, Luca Seitz1, Lisa Christ1, Godehard Scholz1, Odile Stalder3, Florian Kollert1, Stephan Reichenbach1, Peter M Villiger4. 1. Department of Rheumatology, Immunology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2. Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 3. Clinical Trial Unit (CTU), Inselspital, University of Bern, Bern, Switzerland. 4. Department of Rheumatology, Immunology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. peter.villiger@hin.ch.
Abstract
OBJECTIVES: Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ. METHODS: In this observational monocentric study, GCA patients treated with TCZ between the years 2010 and 2018 were studied. Demographic, clinical, and laboratory data were analyzed. RESULTS: A total of 186 patients were included (62% female); 109 (59%) fulfilled the American College of Rheumatology (ACR) criteria, in 123 (66%) patients, large vessel vasculitis was diagnosed by magnetic resonance-angiography (MRA). Cumulative duration of TCZ treatment was 224 years, median treatment duration was 11.1 (IQR 5.6-17.9) months. Glucocorticoids (GC) were tapered over a median of 5.8 (IQR 3.0-8.5) months. At baseline, visual symptoms were present in 70 (38%) and vision loss in 21 (11%) patients. Patients with vision loss at baseline were older (p = 0.032), had a lower C-reactive protein (p = 0.002), and showed a negative association with MRA of the aorta (p = 0.006). Two patients (1.1%) developed vision loss, both at the initiation of TCZ treatment. CONCLUSION: Our data show a very low incidence of vision loss in TCZ-treated patient. The two cases of AION occurred at the initiation of therapy, they support the hypothesis that advanced, and established structural changes of arteries are key factors for this accident. Whether a shorter duration of concomitant GC treatment is risky regarding vision loss needs to be studied.
OBJECTIVES:Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ. METHODS: In this observational monocentric study, GCA patients treated with TCZ between the years 2010 and 2018 were studied. Demographic, clinical, and laboratory data were analyzed. RESULTS: A total of 186 patients were included (62% female); 109 (59%) fulfilled the American College of Rheumatology (ACR) criteria, in 123 (66%) patients, large vessel vasculitis was diagnosed by magnetic resonance-angiography (MRA). Cumulative duration of TCZ treatment was 224 years, median treatment duration was 11.1 (IQR 5.6-17.9) months. Glucocorticoids (GC) were tapered over a median of 5.8 (IQR 3.0-8.5) months. At baseline, visual symptoms were present in 70 (38%) and vision loss in 21 (11%) patients. Patients with vision loss at baseline were older (p = 0.032), had a lower C-reactive protein (p = 0.002), and showed a negative association with MRA of the aorta (p = 0.006). Two patients (1.1%) developed vision loss, both at the initiation of TCZ treatment. CONCLUSION: Our data show a very low incidence of vision loss in TCZ-treated patient. The two cases of AION occurred at the initiation of therapy, they support the hypothesis that advanced, and established structural changes of arteries are key factors for this accident. Whether a shorter duration of concomitant GC treatment is risky regarding vision loss needs to be studied.
Authors: Sabine Adler; Stephan Reichenbach; Andrea Gloor; Daniel Yerly; Jennifer L Cullmann; Peter M Villiger Journal: Rheumatology (Oxford) Date: 2019-09-01 Impact factor: 7.580
Authors: Rod Foroozan; Vincent A Deramo; Lawrence M Buono; D Gerard R Jayamanne; Robert C Sergott; Helen Danesh-Meyer; Peter J Savino Journal: Ophthalmology Date: 2003-03 Impact factor: 12.079
Authors: Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson Journal: N Engl J Med Date: 2017-07-27 Impact factor: 91.245
Authors: Javier Loricera; Santos Castañeda; Clara Moriano; Javier Narváez; Vicente Aldasoro; Olga Maiz; Rafael Melero; Ignacio Villa; Paloma Vela; Susana Romero-Yuste; José L Callejas; Eugenio de Miguel; Eva Galíndez-Agirregoikoa; Francisca Sivera; Jesús C Fernández-López; Carles Galisteo; Iván Ferraz-Amaro; Julio Sánchez-Martín; Lara Sánchez-Bilbao; Mónica Calderón-Goercke; Alfonso Casado; José L Hernández; Miguel A González-Gay; Ricardo Blanco Journal: Ther Adv Musculoskelet Dis Date: 2022-07-22 Impact factor: 3.625